Innovacell Inc. (504A)

Overview

Innovacell Inc. is a pioneering biotechnology company based in Tokyo, Japan, with a significant focus on regenerative medicine products. Established in 2021, the company specializes in the research, development, and manufacturing of innovative therapies, particularly autologous cell therapies that address fecal and urinary incontinence. Innovacell operates a wholly-owned subsidiary in Innsbruck, Austria, and draws upon over two decades of experience from its predecessor, Innovacell Biotechnologie AG, which has been at the forefront of GMP-certified facility operations since 2005. The firm is driven by a mission to address unmet needs in the fields of urology and gastroenterology, maintaining a commitment to low per-dose costs through its proprietary manufacturing site, in operation for more than 15 years. The leadership team, including Co-CEOs Colin Lee Novick and Jason Sieger, CSO Rainer Marksteiner, and CFO Yasushi Hosono, plays a pivotal role in steering the company's journey from preclinical research to Commercialization.

Products and Services

• Regenerative Medicine Products:

  Innovacell specializes in regenerative medicine, focusing on therapies that promote healing and recovery, particularly through the use of cells derived from the patient's own body.

• Autologous Cell Therapies:

  The company focuses on autologous cell therapies, which are treatments that utilize a patient's own cells to treat conditions such as fecal and urinary incontinence.

• ICEF15:

  ICEF15 is Innovacell’s lead candidate—a groundbreaking autologous skeletal muscle-derived cell therapy specifically targeting urge fecal incontinence. This therapy is currently undergoing a multi-regional Phase 3 clinical trial across Japan, Europe, and the US, with patient enrollment initiated in 2022 and 2023.

• Clinical Trials:

  Innovacell is actively involved in clinical trials to evaluate the efficacy and safety of its therapies, with a strong focus on advancing its lead products through the regulatory approval process.

• Manufacturing Services:

  The company operates its own proprietary manufacturing facility that has been functional for over 15 years, allowing Innovacell to maintain low production costs while adhering to strict GMP standards.